SPK Acquisition Corp. intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on operating businesses in the telecommunications, media, and technology sectors in Asia. The company was incorporated in 2020 and is based in Shanghai, China.
IPO Year: 2021
Exchange: NASDAQ
Fastest customizable press release news feed in the world
NAPLES, Fla., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. ("Varian Bio"), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. ("SPK") (NASDAQ:SPK), a special purpose acquisition company ("SPAC"), today announced a joint presentation to discuss the proposed transaction and provide a corporate update. The presentation can be accessed by clicking the link here or by visiting Varian Bio's investor section of its website at www.varianbio.com. Transaction Overview Pursuant to the merger agreement, Varian Bio will merge with a wholly owned subsidiary of SPK, with Varian Bio being the surviving
Varian Biopharmaceutical is developing a proprietary atypical protein kinase C iota inhibitor in multiple formulations for a broad range of tumor typesCombined company expected to have a post-transaction pro forma equity value of approximately $116 million, assuming no redemptions from SPK's existing public shareholdersMerger expected to close in Q2 2022, and the combined company will be listed on NASDAQ under the proposed ticker symbol "VBIO" NAPLES, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. ("Varian Bio"), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. ("SPK") (NASDAQ:SPK), a spec
RW - SPK Acquisition Corp. (0001848097) (Filer)
25-NSE - SPK Acquisition Corp. (0001848097) (Subject)
8-K/A - SPK Acquisition Corp. (0001848097) (Filer)
8-K - SPK Acquisition Corp. (0001848097) (Filer)
10-Q - SPK Acquisition Corp. (0001848097) (Filer)
S-4/A - SPK Acquisition Corp. (0001848097) (Filer)
8-K - SPK Acquisition Corp. (0001848097) (Filer)
DEF 14A - SPK Acquisition Corp. (0001848097) (Filer)
PRER14A - SPK Acquisition Corp. (0001848097) (Filer)
PRER14A - SPK Acquisition Corp. (0001848097) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - SPK Acquisition Corp. (0001848097) (Issuer)
3 - SPK Acquisition Corp. (0001848097) (Issuer)
This live feed shows all institutional transactions in real time.
SC 13G/A - SPK Acquisition Corp. (0001848097) (Subject)
SC 13G/A - SPK Acquisition Corp. (0001848097) (Subject)
SC 13G/A - SPK Acquisition Corp. (0001848097) (Subject)
SC 13G/A - SPK Acquisition Corp. (0001848097) (Subject)
SC 13G - SPK Acquisition Corp. (0001848097) (Subject)
SC 13G - SPK Acquisition Corp. (0001848097) (Subject)
SC 13G - SPK Acquisition Corp. (0001848097) (Subject)
SC 13G - SPK Acquisition Corp. (0001848097) (Subject)
SC 13G - SPK Acquisition Corp. (0001848097) (Subject)
SC 13G/A - SPK Acquisition Corp. (0001848097) (Subject)
Live finance-specific insights
Varian Biopharmaceutical is developing a proprietary atypical protein kinase C iota inhibitor in multiple formulations for a broad range of tumor typesCombined company expected to have a post-transaction pro forma equity value of approximately $116 million, assuming no redemptions from SPK's existing public shareholdersMerger expected to close in Q2 2022, and the combined company will be listed on NASDAQ under the proposed ticker symbol "VBIO" NAPLES, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. ("Varian Bio"), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. ("SPK") (NASDAQ:SPK), a spec